AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 42 min read$WAT

Waters Q3 Earnings Call Highlights

Waters Corporation (WAT) reported Q3 revenue of $575M in Advanced Diagnostics, up 2%, and $500M in Diagnostic Solutions, flat. Microbiology revenue grew 4% outside China but declined 20% in China. Clinical Business Unit revenue rose 17%, and Materials Sciences revenue increased 7%. The company expects to recover revenue from reagent-rental compliance and announced partnerships for its Onclarity HPV kit.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 11:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Waters Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$WATBullishMed
01

Why it matters

The raised guidance and acquisition signal continued growth, but execution risk in AI and China remains.

02

Market read

First disclosure of Q3 results and updated guidance provides fresh material for traders.

03

What to watch

Potential headwinds in China and AI revenue uncertainty could temper the positive impact.

Relevance 8/10Novelty 8/10Timing: post-earnings today

Background

Waters' Q3 earnings call highlighted modest revenue growth, AI initiatives, and a strategic acquisition, followed by an upgraded full‑year outlook.

Company-level read

Ticker impact

$WATBullishHigh confidence
Context

Waters reported Q3 results and raised full-year organic revenue growth guidance, providing new revenue and EPS forecasts.

Expected impact

likely modest upside as market prices in higher growth outlook

Evidence & confidence

The company increased its organic revenue growth outlook by 140 bps and provided EPS guidance above prior expectations, which is new material information.

Market effects

Sector

Higher growth outlook may boost sentiment in the analytical instruments sector.

Regional

U.S. investors may re‑price Waters and peers in the life‑science tools space.

Global

Guidance lift could influence global biotech and pharma customers' procurement plans.

Counterpoint

What could challenge this read

If the guidance increase is modest relative to market expectations, the stock may already be priced in, limiting upside.

Key entities

  • company
    Waters Corporation

    Provider of analytical technologies, ticker WAT.

Read at source← All news

StoryWaters Corp. posts Q3 2026 revenue of $1.767 B, raises full‑year guidance and announces MOBILion acquisition

Also covered by

4 outlets

Related articles

NOV 4
$WATHighAI 8/10

Bernstein raises Waters stock price target to $535 on earnings beat

Bernstein raised its price target on Waters Corp. (WAT) to $535 from $450, citing strong Q3 2026 results. Revenue grew 10% in constant currency, and adjusted EPS of $4.10 beat estimates. The company raised full-year 2026 guidance for revenue and EPS. Bernstein described the 2027 outlook as conservative, with mid-single-digit-plus organic growth expected. Other analysts also raised price targets following the earnings beat.

investing.com2 min
NOV 4
$WATMed

KeyBanc raises Waters stock price target to $500 on guidance boost

KeyBanc raised its price target for Waters Corp. (WAT) to $500 from $460, citing strong Q3 results and raised guidance. WAT reported 10% revenue growth and 30.1% adjusted operating margin, exceeding estimates. The stock is up 52% in six months, trading near $460. Stifel also raised its target to $470 but maintained a Hold rating. WAT's full-year guidance was increased to 9.1%-9.7% growth, with AI and China growth cited as positive factors.

investing.com2 min